Avid Bioservices Inc (CDMO)

[north40000]

Some worthwhile considerations re incipient clinical trials[KarinCA]:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=130797130

"The Uphill Path to Successful Clinical Trials
Keeping Patients Enrolled
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3684189/


Considerations For Improving Patient Recruitment Into Clinical Trials
https://www.clinicalleader.com/doc/considerations-for-improving-patient-0001


How to Reduce Dropouts with Patient Recruitment
http://www.md-events.com/en/life-sciences/news/blog-articles/how-to-reduce-dropouts-with-patient-recruitment/ "

As CP said earlier today:

Jedd Wolchok says: FDA approvals in PHASE I for IO therapy

At index 13:10 the presenter says that in IO approvals are possible in Phase II and Phase III and Wolchok adds: EVEN in PHASE I.
Wolchok on 2017 Immuno-Therapy.

So PPHM's many Phase I trials strategy may be more valuable then we think."